Related Experiment Video

Updated: Jun 1, 2026

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
28:15

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

Published on: July 28, 2010

[Signaling and metabolic predispositions linked to the colorectal cancer]

Stéphanie Olivier1, Anne-Marie Mir, Jean-Claude Michalski

  • 1CNRS-UMR 8576, unité de glycobiologie structurale et fonctionnelle, IFR 147, bâtiment C9, Université de Lille 1, avenue Mendeleiev, Cité scientifique, 59655 Villeneuve d'Ascq, France.

Medecine Sciences : M/S
|May 26, 2011
PubMed

Insights

Nutritional sensing via O-GlcNAcylation may link metabolic disorders to colorectal cancer (CCR). This pathway disruption is implicated in nearly 90% of CCR cases, suggesting a novel therapeutic target.

Area of Science:

  • Oncology
  • Metabolic pathways
  • Molecular biology

Background:

  • Colorectal cancer (CCR) progression involves complex, orchestrated molecular events.
  • Dysregulation of the Wnt/β-catenin pathway is implicated in approximately 90% of CCR cases.
  • Metabolic disorders are known risk factors for CCR, but the underlying mechanisms remain unclear.

Purpose of the Study:

  • To investigate the potential role of O-GlcNAcylation as a link between metabolic disorders and colorectal cancer.
  • To explore how nutritional sensing pathways may contribute to colorectal cancer development.

Main Methods:

  • The study proposes a hypothesis based on existing literature regarding Wnt/β-catenin signaling and metabolic pathways.
  • Analysis of the role of O-GlcNAcylation in controlling the insulin pathway and its connection to cancer.

Main Results:

  • O-GlcNAcylation is a nutritional sensor involved in regulating the insulin pathway.
  • This pathway's dysregulation is hypothesized to connect metabolic disorders to colorectal cancer initiation.

Conclusions:

  • O-GlcNAcylation represents a potential molecular link between metabolic dysfunction and colorectal cancer.
  • Targeting O-GlcNAcylation may offer a novel therapeutic strategy for CCR prevention and treatment.

More Related Videos

In vitro Organoid Culture of Primary Mouse Colon Tumors07:33

In vitro Organoid Culture of Primary Mouse Colon Tumors

Published on: May 17, 2013

Related Concept Videos

Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...